Cardiovascular diseases are a major public health problem in Russia, with mortality rates from CVD two to three times higher than in developed countries. CVD also have a significant economic impact in Russia, accounting for 80% of indirect costs from lost productivity. A global study found surprisingly low use of inexpensive medications for secondary prevention of CVD in both high- and low-income countries, representing a huge missed opportunity to help millions of people with heart disease.